My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Br J Haematol. 1999 May;105(2):556-9.

    A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease.

    Franco RF, Morelli V, Lourenço D, Maffei FH, Tavella MH, Piccinato CE, Thomazini IA, Zago MA.

    Department of Clinical Medicine, School of Medicine of Ribeirão Preto, 14048900 Ribeirão Preto-SP, Brazil. rendri@hotmail.com

    Erratum in:

    • Br J Haematol 1999 Jul;106(1):264.

    We assessed the effect of a recently described mutation in the MTHFR gene (1298 A --> C) on the risk of deep venous thrombosis (DVT) by determining its prevalence in 190 patients with verified DVT and in age-, race- and gender-matched controls. MTHFR 1298 A --> C was found in 42.1% of patients and in 41.1% of controls. The OR for venous thrombosis was 1.07 (95% CI 0.70-1.65) for heterozygotes and 0.83 (95% CI 0.33-2.08) for homozygotes. The OR for the factor V Leiden (FVL) mutation was 3.40 (95% CI 1.22-9.48), for FII 20210 G --> A was 5.22 (95% CI 1.12-24.2) and for MTHFR 677 C --> T, 1.24 (95% CI 0.82-1.87). No significant increased risk for venous thrombosis was found when MTHFR 1298 A --> C was coinherited with FVL (OR 2.85, 95% CI 0.88-9.23), FII 20210 G --> A (OR 7.19, 95% CI 0.87-59.4) or MTHFR 677 C --> T (OR 1.44, 95% CI 0.71-2.92). These data do not support a critical role of MTHFR 1298 A --> C in the predisposition to DVT.

    PMID: 10233437 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read
    Write to the Help Desk